Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | Updates in the management of CAR-T toxicities

Sattva Neelapu • 19 Jun 2019
ICML 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T

A new consensus grading system for cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and cytopenias, potential side effects of CAR T-cell therapy, has been proposed. This is discussed here by Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Sattva Neelapu

Five-year follow-up of the ZUMA-5 trial investigating axi-cel in R/R indolent NHL 4:50
Five-year follow-up of the ZUMA-5 trial investigating axi-cel in R/R indolent NHL
Sattva Neelapu • 12 Dec 2024
Next steps with ADI-001 0:42
Next steps with ADI-001
Sattva Neelapu • 5 Jun 2022
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma 2:06
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
Sattva Neelapu • 5 Jun 2022
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies 3:24
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
Sattva Neelapu • 5 Jun 2022

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals